NEKTAR THERAPEUTICS's gross profit margin for the first quarter of its fiscal year 2015 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. NEKTAR THERAPEUTICS is extremely liquid. Currently, the Quick Ratio is 4.36 which clearly shows the ability to cover any short-term cash needs. NKTR managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 888.10% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY15||Q1 FY14|
|Net Sales ($mil)||108.8||19.77|
|Net Income ($mil)||33.82||-46.2|
|Balance Sheet||Q1 FY15||Q1 FY14|
|Cash & Equiv. ($mil)||325.81||284.07|
|Total Assets ($mil)||499.21||487.01|
|Total Debt ($mil)||256.36||253.18|
|Profitability||Q1 FY15||Q1 FY14|
|Gross Profit Margin||42.29||-167.61|
|Return on Assets||5.22||-31.44|
|Return on Equity||33.76||0.0|
|Debt||Q1 FY15||Q1 FY14|
|Share Data||Q1 FY15||Q1 FY14|
|Shares outstanding (mil)||131.45||126.94|
|Div / share||0.0||0.0|
|Book value / share||0.59||-0.08|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1836393.0||1459406.0|
HOLD. NEKTAR THERAPEUTICS's P/E ratio indicates a significant premium compared to an average of 33.24 for the Pharmaceuticals industry and a significant premium compared to the S&P 500 average of 21.18. For additional comparison, its price-to-book ratio of 21.63 indicates a significant premium versus the S&P 500 average of 2.82 and a significant premium versus the industry average of 11.85. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, NEKTAR THERAPEUTICS proves to trade at a premium to investment alternatives within the industry.
|NKTR 74.82||Peers 33.24||NKTR NM||Peers 24.85|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.
NKTR is trading at a significant premium to its peers.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
NKTR's P/CF is negative making the measure meaningless.
|NKTR NM||Peers 18.88||NKTR 2.42||Peers 1.00|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
NKTR's ratio is negative making this valuation measure meaningless.
Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
NKTR trades at a significant premium to its peers.
|NKTR 21.63||Peers 11.85||NKTR 113.17||Peers 21.38|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
NKTR is trading at a significant premium to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
NKTR is expected to have an earnings growth rate that significantly exceeds its peers.
|NKTR 5.77||Peers 9.52||NKTR 98.87||Peers 8.60|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
NKTR is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
NKTR has a sales growth rate that significantly exceeds its peers.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV